Come listen to MedSIR Founders Maria Campos, Dr. Javier Cortés, and Dr. Antonio Llombart speak about the MedSIR concept and how we are currently optimizing clinical research in Oncology.

Don’t miss Dr. José Perez, Breast Cancer Specialist, speaking about the role MedSIR plays in his everyday research.

WELCOME TO MEDSIR!

Here we are dedicated to the design and management of clinical trials involving some of the most important current drugs in Oncology such as osimertinib, pembrolizumab, pertuzumab, T-DM1, olaparib, niraparib, eribulin, palbociclib, fulvestrant, radium-223 and many more and we’d be thrilled to help you transform your idea into a high-level strategic clinical trial by applying our simple method:

First off, you confidentially send us your idea… a few lines, or a short synopsis is all we need.

Then, your idea will be reviewed by our network of cancer experts while our statistician develops a realistic scenario for the study to be carried out.

Lastly, we confidentially present the proposal to a potential funder, negotiating a win-win situation that satisfies all parties.

If the project is approved, you will join our team and play a lead role in all study aspects all the way through to the publication of study results. Meanwhile, our clinical operations team professionally manages the trial, respecting ISO 9001-certified quality, while placing a major focus on accrual timelines: The faster we move, the quicker we can produce results and improve patient lives.


The Beginning of the LUZERN Study

Last 11th November 2019, it was submitted the LUZERN study to AEMPS and CEIm with the participation of 10 different sites in Spain. Overall, we expect to recruit a total of 23 patients. Sites activation is...
READ MORE...
A New Trial On Board: The ORPHEUS Study

MedSIR will soon begin the ORPHEUS study “A Multicenter, Open-Label, Single-Arm, Phase II Clinical Trial to Evaluate the Efficacy and Safety of INCMGA00012 in Advanced Penile Squamous...
READ MORE...
Last Patient Last Visit for Interim Analysis in PHERGain Study

A new milestone of PHERGain study-Chemotherapy-free trastuzumab and pertuzumab in HER2-positive breast cancer: FDG-PET response-adapted strategy-has been achieved...
READ MORE...
Liquid biopsy and ctDNA: the winner tandem

Precision medicine is an approach to patient care that allows doctors to select treatments that are most likely to help patients based on a genetic understanding of their disease. Recent advances in science...
READ MORE...
50% Recruitment Achieved in BARBICAN Study

A new milestone achieved in BARBICAN Study! 20 Spanish patients have been successfully randomized in the study, reaching 50% recruitment in Spain. The last patient to be randomized by Dr. Stradella...
READ MORE...
ESMO Congress 2019 Highlights

The MedSIR Project Development team attended the 2019 annual meeting of the European Society of Molecular Oncology. ESMO is one of the most important professional organizations for medical oncology in the world...
READ MORE...